Letrozol Stada

Letrozole, the active ingredient in Letrozol Stada, is an aromatase inhibitor presented as a tablet for oral use. It reduces estrogen production and is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women as part of adjuvant therapy after surgery.

GNH USA supplies Letrozol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, with consistent quality and regulatory compliance. We provide reliable logistics and support for bulk and individual orders across multiple regions.

Letrozole acts on estrogen‑dependent pathways in breast cancer and is indicated for the following conditions:

Hormone receptor‑positive early‑stage breast cancer (postmenopausal): Improves disease‑free survival when given as adjuvant therapy after surgery. Metastatic hormone receptor‑positive breast cancer (postmenopausal): Provides hormonal control to delay disease progression. Adjuvant treatment of early‑stage breast cancer (postmenopausal): Reduces risk of recurrence when combined with other therapies. Locally advanced breast cancer (postmenopausal): Used to shrink tumors before surgery.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: Sudden feeling of warmth, often with sweating. - Joint and muscle pain: Arthralgia or myalgia affecting daily activities. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Mild to moderate upset stomach.

Serious or Rare Side Effects: - Severe liver injury: Elevated transaminases or hepatic failure. - Bone fracture: Increased risk of osteoporosis‑related fractures. - Pulmonary embolism: Sudden shortness of breath and chest pain. - Anaphylaxis: Life‑threatening allergic reaction with rash, swelling, and airway compromise.

Before initiating Letrozole therapy, clinicians should evaluate several safety considerations.

Bone health assessment: Monitor bone mineral density and consider calcium/vitamin D supplementation. Liver function monitoring: Check baseline hepatic enzymes and repeat periodically. Cardiovascular risk review: Assess history of thromboembolic events or hyperlipidaemia. Menopausal status verification: Avoid use in premenopausal women unless ovarian suppression is confirmed. Concomitant medication review: Evaluate for drugs that may alter letrozole metabolism. Store at ambient temperature: Keep tablets in the original container, protect from moisture and light.

Letrozole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Tamoxifen: Antagonistic effect reduces therapeutic benefit of letrozole. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): Significantly lower plasma concentrations, diminishing efficacy. - Estrogen‑containing hormone therapy: Counteracts estrogen suppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): May increase letrozole levels, requiring observation. - Warfarin: Potential alteration of anticoagulant effect; monitor INR. - Cholesterol‑lowering agents (statins): Possible increased risk of muscle toxicity; assess symptoms.